1131PTranscriptome signatures of treatment responses in a preoperative window of opportunity trial of nivolumab and tadalafil in resectable squamous cell carcinoma of the head and neck
ConclusionsThese results point to diverse intratumoral immune states triggered by nivolumab/tadalafil in HPV(+) when compared to HPV(-) SCCHNs. They challenge the notion that increased presence of intratumoral T lymphocytes alone is associated with favorable therapeutic responses to PD1 inhibition in SCCHN. Yet, select pretreatment transcripts associated with innate and/or adaptive immune responses may have prognostic relevance.Clinical trial identificationNCT 03238365.Legal entity responsible for the studyThe authors.FundingBristol-Myers Squibb.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
3OSystemic gut microbial metabolites limit the anti-tumour effect of CTLA-4 blockade in hosts with cancer
ConclusionsAltogether, these results suggested that gut microbial metabolites might favor an immune tolerance profile that limits anti-CTLA-4 activity.Legal entity responsible for the studyInstitut Gustave Roussy.FundingThis study was funded by Gustave Roussy Cancer Campus, Fondation Gustave Roussy, the Institut national de la sant é et de la recherche médicale (INSERM), the Centre national de la recherche scientifique (CNRS), SIRIC SOCRATE (INCa DGOS INSERM 6043), SIRIC SOCRATE 2.0 (INCa-DGOS-INSERM_12551), MMO program: ANR-10IBHU-0001); Direction General de l’Offre de Soins (DGOS; TRANSLA 12-174); Institut National d...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
459PProof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer
ConclusionsVCN-01 replicates and expresses hyaluronidase after intratumor injection both in preclinical models and in patients with pancreatic cancer. Enhanced chemotherapy access and reduction of tumor stiffness favours local control of pancreatic tumours treated with VCN-01 + standard of care.Clinical trial identificationEudraCT: 2012-005556-42.Legal entity responsible for the studyVCN Biosciences.FundingVCN Biosciences.DisclosureM. Hidalgo: Advisory / Consultancy, Speaker Bureau / Expert testimony: Celgene; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy: Novartis; Advisory...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1579PPrognostic factors for non-small cell lung cancer patients with driver mutation negative and brain metastases (HOT 1701)
ConclusionsPrognosis of NSCLC patients with EGFR, ALK negative and BM is poor. In addition to the known prognostic factors such as DS-GPA, this study shown that male, T factor, N factor, and histological type of non-adenocarcinoma, had a prognostic role in NSCLC patients with driver mutation negative and BM.Clinical trial identificationUMIN000030313, 08/12/2017.Legal entity responsible for the studyHokkaido Lung Cancer Clinical Study Group Trial: HOT.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
237PThe value of genetic counselling in breast cancer genetic testing and clinical management
ConclusionsGenetic counselling provides significant psychosocial and practical benefits in the provision of breast cancer genetics: including advice for the whole family, ensuring genetic testing is appropriate and referral to appropriate external healthcare agencies. 1 NICE Guidance 2 NCCN Guidelines.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureV. Kiesel: Shareholder / Stockholder / Stock options: Genehealth UK. G. Wishart: Shareholder / Stockholder / Stock options: Check4Cancer. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
460PA phase Ia/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumours
ConclusionsThe oral small molecule AXL kinase inhibitor TP-0903 is well tolerated with a manageable safety profile. Hematologic toxicity was observed as a DLT. Future studies will evaluate the role of TP0903 in selected disease cohorts as monotherapy and in combination. Serum soluble AXL will be evaluated as a potential predictive biomarker of response.Clinical trial identificationNCT: 02729298.Legal entity responsible for the studyTolero Pharmaceuticals, Inc.FundingTolero Pharmaceuticals, Inc.DisclosureJ. Sarantopoulos: Research grant / Funding (institution): Tolero. G. Fotopoulos: Research grant / Funding (institution): ...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1580PA novel risk classification system based on nomogram scores to predict survival of patients presenting with brain metastases at the first diagnosis of NSCLC
ConclusionsWe established a risk stratification system based on nomogram scores to predict the OS of patients presenting with BMs at initial diagnosis of NSCLC. These predictive models can act as auxiliary tools to guide treatment strategies and prognostic evaluation.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1132PRisk and impact of renal impairment of locally advanced head and neck squamous cell carcinoma patients who received chemoradiotherapy with cisplatin
ConclusionsAlmost one third of locally advanced HNSCC patients who underwent CRT with cisplatin developed AKD with peak incidence at 3 months after CRT. After 1 year, eGFR of patients with AKD had not recovered, and remained at -30% below baseline. ECOG 0 and hypertension were a predictor for AKD. Hypertension might reflect underlying kidney disease which leads to susceptibility to kidney injury. Moreover, physician ’s awareness of AKD and underestimation of potential complications in fit patients might explain these findings.Legal entity responsible for the studyThe authors.FundingHas not received any funding.Disclosure...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
4ONovel dendritic cell based immunotherapy for advanced cancer
ConclusionsThe number and phenotype of nDC are suppressed in advanced cancer patients. Inhibition of p38 MAPK can restore the function of patient cDC2 subset. Co-culture of these p38-inhibited cDC2 with pDC further show promising results important for developing advanced DC vaccines. Our study has paved the way for a phase I clinical trial of adoptive transfer of p38-MAPK inhibited cDC2 in 24 advanced cancer patients.Legal entity responsible for the studyUniversity of Nottingham.FundingUniversity of Nottingham.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
238PElderly patients in the Japanese breast cancer registry
ConclusionsElderly patients suffered from more advanced disease at the time of diagnosis. Irradiation after BCS and primary systemic chemotherapy was more frequently omitted in the elderly patients. Overall, BCSS was similar among ages, but the rate of other causes of death was higher in elderly patients.Legal entity responsible for the studyThe authors.FundingJapanese Breast Cancer Society.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
461PFirst in human phase I/IIa study of PEN-866, a heat shock protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumours: Phase I results
ConclusionsPEN-866 appears well tolerated with an expected adverse event profile and preliminary evidence of antitumor activity. PEN-866 will be evaluated in phase 2a expansion cohorts (NCT03221400).Clinical trial identificationNCT03221400 July 18, 2017.Legal entity responsible for the studyTarveda Therapeutics, Inc.FundingTarveda Therapeutics, Inc.DisclosureJ.C. Bendell: Research grant / Funding (institution): Tarveda Therapeutics; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses, Advisory/Consultancy to Institution: Gilead; Advisory / Consultancy, Research grant / Funding ...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1133PSystemic bevacizumab for the treatment of recurrent respiratory papillomatosis: A retrospective analysis from an academic tertiary care center
ConclusionsSystemic bevacizumab appears to be a safe and well tolerated treatment option for patients with severe RRP. It demonstrates promising efficacy on symptoms including voice quality and improved breathing as well as decreased requirement for surgical therapy.Legal entity responsible for the studyThe author.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1581PComparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC)
ConclusionsData curated from EHRs of rw patients with aNSCLC can provide estimates of response rates that are comparable to RECIST-based response rates observed in similar patient populations studied in clinical trial settings. These findings demonstrate the potential of leveraging rw cohorts as a comparator to single arm clinical trials in oncology.Legal entity responsible for the studyFlatiron Health, Inc.FundingFlatiron Health Inc., independent subsidiary of the Roche group.DisclosureX. Ma: Full / Part-time employment, Flatiron Health, Inc. is an independent subsidiary of the Roche Group.: Flatiron Health, Inc.; Shareho...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
239PTumour-infiltrating lymphocytes and BRCA-like status in stage III breast cancer patients treated with intensified carboplatin-based chemotherapy
ConclusionsIn this high-risk breast cancer cohort, high TILs were associated with TNBC and BRCA1-like status. Within the ER-positive subgroup, TIL levels were higher in BRCA1-like compared to non-BRCA-like tumours, but this was not seen within the TNBC subgroup. When adjusted for clinical characteristics, TIL levels were significantly associated with a more favourable outcome in stage III BC patients.Legal entity responsible for the studyThe authors.FundingDutch Cancer Society.DisclosureA. Cimino-Mathews: Research grant / Funding (self): BMS. S.C. Linn: Advisory / Consultancy, Research grant / Funding (institution): AstraZ...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
5PDThe role of EGFR inhibitor (EGFRi) in immune cell infiltration and CD8+ T-cell activation in EGFR mutant lung cancer
ConclusionsThese results provide evidence that EGFRi has the capacity to facilitate modulation of the tumor microenvironment to favor immune cell infiltration and promote T-cell mediated antitumor immunity.Legal entity responsible for the studyThe University of Texas MD Anderson Cancer Center.FundingTianjin HengJia Biotechnology Development Co., Ltd.DisclosureF. Li: Shareholder/Stockholder/Stock options: Tianjin HengJia Biotechnology Development Co., Ltd.. G. Lizee: Advisory/Consultancy: HengJia Neoantigen Biotechnology (Tianjin) Co., Ltd.. P. Hwu: Advisory/Consultancy: Dragonfly Therapeutics; Advisory/Consultancy: GlaxoSm...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
